Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24531742 | 1.00 | FDPS (0.50) | FDPSKMT2ACYP2D6MEN1LMNA | |
| SCHEMBL19820361 | 1.00 | FDPS (0.50) | FDPSKMT2ACYP2D6MEN1LMNA | |
| Hydrochloric Acid SCHEMBL5709804 | 0.98 | FDPS (0.49) | FDPSKMT2ACYP2D6MEN1LMNA | |
| Hydrochloric Acid SCHEMBL31436221 | 0.98 | FDPS (0.49) | FDPSKMT2ACYP2D6MEN1LMNA | |
| Hydrochloric Acid SCHEMBL29642935 | 0.98 | FDPS (0.49) | FDPSKMT2ACYP2D6MEN1LMNA | |
| SCHEMBL31436261 | 0.94 | — | — | |
| SCHEMBL3830497 | 0.94 | — | — | |
| SCHEMBL4152747 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL5709800 | 0.92 | FDPS (0.42) | FDPSKMT2ACYP2D6MEN1LMNA | |
| SCHEMBL11666395 | 0.83 | FDPS (0.53) | FDPSKMT2ACYP2D6MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497364-B2 | Compound for the determination of the protein FKBP12 and a sensor unit comprising it | UNIVERSITA DEGLI STUDI DI FIRENZE (IT) | 2025-12-16 | — | — | US | claimed |
| WO-2017024010-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| EP-1606283-B1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1901747-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | Ingenium Pharmaceuticals AG (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2006125616-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS AG (DE) | 2006-11-30 | — | — | WO | claimed |
| US-7135575-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2006-11-14 | — | — | US | claimed |
| EP-1606244-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | claimed |
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | claimed |
| WO-2004037769-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| CN-1100777-C | N-heterocyclic derivatives as NOS inhibitor | BERLEX LAB (US) | 2003-02-05 | — | — | CN | claimed |
| CN-1252799-A | N-heterocyclic derivatives as NOS inhibitor | BERLEX LAB (US) | 2000-05-10 | — | — | CN | claimed |
| US-4791199-A | Process for antiarrhythmic 1,3-diazabicyclo[4.4.0]dec-2-en-4-ones | G. D. SEARLE & CO. (US) | 1988-12-13 | — | — | US | claimed |
| EP-0234331-A1 | Octahydropyrido[1,2-c]-pyrimidinones | G.D. Searle & Co. (US) | 1987-09-02 | — | — | EP | claimed |
| EP-0215477-A1 | Process and intermediates for antiarrhytmic 1,3-diazabicyclo/4.4.0/dec-2-en-4-ones | G.D. Searle & Co. (US) | 1987-03-25 | — | — | EP | claimed |
| WO-2025125302-A1 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| EP-0823254-A1 | NOVEL USE OF PYRAZOLOPYRIDINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
| EP-0234331-A1 | Octahydropyrido[1,2-c]-pyrimidinones | G.D. Searle & Co. (US) | 1987-09-02 | — | — | EP | disclosed |
| US-4680295-A | ANTIARRHYTHMIA AGENTS | G. D. SEARLE & CO. (US) | 1987-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | FDPS 1236/4885KMT2A 3330/4885CYP2D6 788/4885 |
| US-12497364-B2 | Compound for the determination of the protein FKBP12 and a sensor unit comprising it | FKBP14, FKBP5, FKBP1A | FDPS 407/4885KMT2A 4654/4885CYP2D6 2705/4885 |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | FDPS 1236/4885KMT2A 3330/4885CYP2D6 788/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | FDPS 427/4885KMT2A 4129/4885CYP2D6 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.